Condition: Colorectal Cancer Metastatic · Microsatellite Stable Colorectal Carcinoma · Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer · Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
This description comes directly from the study's public registry record.
Oriana Nanni · 0543739266 · oriana.nanni@irst.emr.it
Bernadette Vertogen · 0544286058 · bernadette.vertogen@irst.emr.it
Always discuss trial participation with your own doctor first.
| IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l. | Meldola, Forlì Cesena, Italy | Recruiting |
| Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card.G.Panico" | Tricase, Lecce, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06522919